GlaxoSmithKline - Enterprise Tech Ecosystem Series

GlaxoSmithKline - Enterprise Tech Ecosystem Series

Summary

GlaxoSmithKline Plc (GSK) is a healthcare company that focuses on developing, manufacturing and commercializing pharmaceuticals, vaccines and consumer healthcare products. It offers drugs for the treatment of diseases such as HIV, respiratory, cancer, immuno-inflammation, anti-viral, central nervous system (CNS), metabolic, cardiovascular and urogenital, anti-bacterial, dermatology and rare diseases. The company also offers over-the-counter (OTC) products for pain relief, oral health, nutrition, skin health and gastro-intestinal diseases. GSK’s vaccine portfolio covers various diseases including hepatitis, diphtheria, tetanus, whooping cough, rotavirus and HPV infections, measles and bacterial meningitis, among others. The company sells its products through wholesalers, pharmacies, hospitals, physicians and other groups worldwide.

In December 2021, GSK and the University of Oxford has entered five-year collaboration to establish Oxford-GSK Institute. The institute aims to improve the success and speed of research and development of new medicines, by building on insights from human genetics and using advanced technologies such as functional genomics and machine learning.

The report provides information and insights into GlaxoSmithKline's tech activities, including -

• Insights of its digital transformation strategies and innovation programs
• Overview of technology initiatives covering partnerships, product launches and investments
• Insights on each technology initiative including technology theme, objective, and benefits
• Details of estimated ICT budgets and major ICT contracts

Scope

• GSK is harnessing the power of digital technologies such as AI, ML, and deep learning to accelerate drug discovery and development process; to reduce the time and operational costs involved in the drug discovery development process; and to improve products quality and enhance customer experience. GSK also signed strategic partnership with AI providers such as Insilico Medicine, Cisco, Cerebras, Viome and IBM.
• GSK is developing core capabilities around AI and ML technologies to improve its ability to understand and interpret genomic data and genetics, and is making huge investments in functional genomics, applying different techniques, such as CRISPR technology, for gene modification to help discover and validate potential targets.
• GSK is focused on incorporating data and analytics to digitalize its manufacturing processes. It created a data analytics platform using Cloudera’s Hadoop open-source software to curate and internally share unstructured and structured scientific data from different operational sources including drug development and clinical trials data.
• GSK integrated IBM’s Watson virtual assistant into its online messaging and chat channels, CRM systems, databases, and many in-house applications. The company launched various bots to engage with customers and resolve inquires, enabling improved customer experience and reduce overall workload.

Reasons to Buy

• Gain insights into GSK's tech operations.
• Gain insights into its tech strategies and innovation initiatives.
• Gain insights into its technology themes under focus.
• Gain insights into various product launches, partnerships and investment strategies.